دورية أكاديمية
أعرض في EDS

Narrow interval dual phase 18F-FDG PET/CT: A practical approach for distinguishing tumor recurrence from radiation necrosis in brain metastasis.

التفاصيل البيبلوغرافية
العنوان: Narrow interval dual phase 18F-FDG PET/CT: A practical approach for distinguishing tumor recurrence from radiation necrosis in brain metastasis.
المؤلفون: Aggarwal A; Department of Computer Science, Cornell University, Ithaca, NY.; Research Intern at Johnston Willis Hospital, Department of Radiology, Richmond, VA., Aggarwal AK; Research Intern at Johnston Willis Hospital, Department of Radiology, Richmond, VA.; High school senior at Collegiate School, Richmond, VA., Prakash S; Research Intern at Johnston Willis Hospital, Department of Radiology, Richmond, VA.; Undergraduate student at Wake Forest University, NC., Vile DJ; Department of Gamma Knife and Neuroscience Center, Johnston Willis Hospital, Richmond, VA.; Hospital Corporation of America, Richmond, VA., Aggarwal A; Johnston Willis Hospital, Department of Radiology, Richmond, VA.; Radiology Associates of Richmond, Richmond, VA.
المصدر: Medicine [Medicine (Baltimore)] 2024 May 03; Vol. 103 (18), pp. e37789.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Positron Emission Tomography Computed Tomography*/methods , Fluorodeoxyglucose F18* , Brain Neoplasms*/secondary , Brain Neoplasms*/diagnostic imaging , Brain Neoplasms*/radiotherapy , Radiation Injuries*/diagnostic imaging , Radiation Injuries*/etiology , Radiation Injuries*/pathology , Neoplasm Recurrence, Local*/diagnostic imaging , Radiopharmaceuticals*, Humans ; Female ; Male ; Middle Aged ; Aged ; Adult ; Diagnosis, Differential ; Necrosis/diagnostic imaging ; Brain/diagnostic imaging ; Brain/pathology ; Magnetic Resonance Imaging/methods ; ROC Curve
مستخلص: Purpose of our research is to demonstrate efficacy of narrow interval dual phase [18F]-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in distinguishing tumor recurrence (TR) from radiation necrosis (RN) in patients treated for brain metastases. 35 consecutive patients (22 female, 13 male) with various cancer subtypes, lesion size > 1.0 cm3, and suspected recurrence on brain magnetic resonance imaging (MRI) underwent narrow interval dual phase FDG-PET/CT (30 and 90 min after tracer injection). Clinical outcome was determined via sequential MRIs or pathology reports. Maximum standard uptake value (SUVmax) of lesion (L), gray matter (GM), and white matter (WM) was measured on early (1) and delayed (2) imaging. Analyzed variables include % change, late phase, and early phase for L uptake, L/GM uptake, and L/WM uptake. Statistical analysis (P < .01), receiver operator characteristic (ROC) curve and area under curve (AUC) cutoff values were obtained. Change in L/GM ratio of > -2% was 95% sensitive, 91% specific, and 93% accurate (P < .001, AUC = 0.99) in distinguishing TR from RN. Change in SUVmax of lesion alone was the second-best indicator (P < .001, AUC = 0.94) with an ROC cutoff > 30.5% yielding 86% sensitivity, 83% specificity, and 84% accuracy. Other variables (L alone or L/GM ratios in early or late phase, all L/WM ratios) were significantly less accurate. Utilizing narrow interval dual phase FDG-PET/CT in patients with brain metastasis treated with radiation therapy provides a practical approach to distinguish TR from RN. Narrow time interval allows for better patient comfort, greater efficiency of PET/CT scanner, and lower disruption of workflow.
Competing Interests: The authors have no funding and conflicts of interest to disclose.
(Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.)
References: Neurosurg Clin N Am. 2020 Oct;31(4):575-587. (PMID: 32921353)
Eur J Nucl Med Mol Imaging. 2020 Jun;47(6):1400-1411. (PMID: 31773234)
Breast. 2022 Oct;65:98-103. (PMID: 35921799)
Handb Clin Neurol. 2018;149:89-112. (PMID: 29307364)
Acad Radiol. 2022 Sep;29(9):1320-1331. (PMID: 34896001)
World Neurosurg. 2021 Jul;151:e1059-e1068. (PMID: 34052453)
Ann Oncol. 2021 Nov;32(11):1332-1347. (PMID: 34364998)
Clin Neurol Neurosurg. 2019 Apr;179:14-18. (PMID: 30784894)
Radiographics. 2012 Sep-Oct;32(5):1343-59. (PMID: 22977022)
Clin Nucl Med. 2022 Sep 1;47(9):800-806. (PMID: 35695724)
AJNR Am J Neuroradiol. 2015 Dec;36(12):2250-5. (PMID: 26427832)
Pancreas. 2015 May;44(4):655-9. (PMID: 25815646)
J Neuroimaging. 2018 Jan;28(1):118-125. (PMID: 28718993)
J Neurooncol. 2011 May;103(1):137-46. (PMID: 20838854)
Neuro Oncol. 2019 May 6;21(5):585-595. (PMID: 30615138)
Neuro Oncol. 2017 Feb 1;19(2):162-174. (PMID: 28391295)
Neurosurg Clin N Am. 2020 Oct;31(4):481-488. (PMID: 32921345)
Int J Mol Sci. 2014 Jul 03;15(7):11832-46. (PMID: 24995696)
Minim Invasive Neurosurg. 2005 Aug;48(4):228-34. (PMID: 16172969)
AJNR Am J Neuroradiol. 2017 Aug;38(8):1520-1527. (PMID: 28619837)
AJR Am J Roentgenol. 2020 Oct;215(4):985-996. (PMID: 32841063)
Neuro Oncol. 2016 Jun;18(6):873-80. (PMID: 26688076)
Int J Cancer. 2001 Jun 20;96(3):191-7. (PMID: 11410888)
J Nucl Med. 2001 Sep;42(9):1412-7. (PMID: 11535734)
J Neurooncol. 2012 Aug;109(1):149-58. (PMID: 22638727)
Nat Rev Neurol. 2017 May;13(5):279-289. (PMID: 28387340)
Eur J Nucl Med. 2001 Jun;28(6):696-703. (PMID: 11440029)
Eur J Nucl Med Mol Imaging. 2003 Jan;30(1):96-100. (PMID: 12483415)
Int J Mol Sci. 2019 Dec 29;21(1):. (PMID: 31905745)
المشرفين على المادة: 0Z5B2CJX4D (Fluorodeoxyglucose F18)
0 (Radiopharmaceuticals)
تواريخ الأحداث: Date Created: 20240503 Date Completed: 20240503 Latest Revision: 20240507
رمز التحديث: 20240507
مُعرف محوري في PubMed: PMC11062716
DOI: 10.1097/MD.0000000000037789
PMID: 38701250
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-5964
DOI:10.1097/MD.0000000000037789